Last update Oct. 17, 2016

Tolterodine Tartrate

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Antimuscarinic agent with atropine-like action.

At latest update no published data on excretion into breast milk were found.

A high plasma protein-binding capacity makes it unlikely its passage into breast milk.
Its low oral bioavailability hinders the passage from ingested milk towards the infant’s plasma, except in preterm babies and immediate neonatal period, which may show an increased intestinal permeability. There are few poor metabolizers (CYP2D6 deficient) who may exhibit increasing oral bioavailability to 66%

Take as smallest dose as possible and avoid long-term use since anticholinergics can reduce milk production.

Monitoring anticholinergic symptoms in infants (dry mouth, constipation ..) is warranted.

Alternatives

  • Oxybutynin (Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Tolterodine Tartrate in other languages or writings:

Group

Tolterodine Tartrate belongs to this group or family:

Tradenames

Main tradenames from several countries containing Tolterodine Tartrate in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 17 %
Molecular weight 476 daltons
Protein Binding 96 %
VD 1.6 l/Kg
Tmax 1 - 3 hours
T½ 1.9 - 3.7 hours

References

  1. Pfizer. Tolterodine. Drug Summary. 2015 Full text (in our servers)
  2. AEMPS. Tolterodina. Ficha técnica. 2012 Full text (in our servers)
  3. Bizzarro A, Iannucci F, Tolino A, Soricelli A, Guarino G, Verdoliva A. Inhibiting effect of atropine on prolactin blood levels after stimulation with TRH. Clin Exp Obstet Gynecol. 1980 Abstract
  4. De Martino F, De Matteo A, L'Abbate V, Soricelli A, Fontana A, Petrenga E, Cesarone M. [Inhibitory effects of atropine on serum prolactin levels after TRH stimulation]. Boll Soc Ital Biol Sper. 1980 Abstract

Total visits

9,462

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM